The TASC Trial: Therapeutic vs Prophylactic Anticoagulation for Acute Chest Syndrome
The TASC trial was the first phase 3 RCT to investigate if therapeutic-dose tinzaparin could shorten acute chest syndrome (ACS) duration in adults with sickle cell disease without pulmonary artery macrothrombosis. The study found that therapeutic-dose tinzaparin reduced time to ACS resolution compared with prophylactic doses, and also resulted in significantly lower opioid consumption. Clinically, this suggests a potential role for higher-dose anticoagulation in managing ACS refractory to current supportive care.
The TASC trial was the first phase 3 RCT to investigate if therapeutic-dose tinzaparin could shorten acute chest syndrome (ACS) duration in adults with sickle cell disease without pulmonary artery macrothrombosis. The study found that therapeutic-dose tinzaparin reduced time to ACS resolution compared with prophylactic doses, and also resulted in significantly lower opioid consumption. Clinically, this suggests a potential role for higher-dose anticoagulation in managing ACS refractory to current supportive care.
Show moreShow less
The TASC trial was the first phase 3 RCT to investigate if therapeutic-dose tinzaparin could shorten acute chest syndrome (ACS) duration in adults with sickle cell disease without pulmonary artery macrothrombosis. The study found that therapeutic-dose tinzaparin reduced time to ACS resolution compared with prophylactic doses, and also resulted in significantly lower opioid consumption.